Prostate cancers (PCs), initially responsive to anti-androgen therapies, often advance to a hormone-refractory 'castrate-resistant' PC (CRPC) stage. However, the androgen receptor (AR) pathway remains active and key for cell growth and gene expression within tumours, even in the apparent absence of hormone. Proposed mechanisms to explain progression, including AR amplification/mutation, are insufficient to completely explain CRPC and possible roles of AR cofactors such as prohibitin (PHB) are poorly understood. We investigated whether PHB loss could sensitise PC cells and tumours to adrenal gland-derived androgens, which persist even after androgen ablation, hence contribute to development of CRPC. Using a pair of PC cell lines, inducibly expressing ectopic cDNA or RNAi for PHB, responses to different androgens and hormone concentrations were studied both in vitro and in vivo. PHB was found at the promoters of several genes, both AR and non-AR-regulated, and knockdown increased histone acetylation at these promoters. Further, PHB knockdown increased the rate of AR ligand-induced chromatin binding, and binding rate and occupancy of AR upon the PSA promoter. This resulted in increased cell growth and AR activity in response to all androgens, including promoting a response to the weaker adrenal androgens previously absent at physiological concentrations. In vivo this had functional consequences such that PHB knockdown resulted in androstenedione being sufficient to promote tumour growth, under conditions mimicking those in patients undergoing androgen ablation therapy. We conclude that reduction in PHB levels is sufficient to lower the threshold of AR activity in vitro and in vivo; this may be via a general increase in histone acetylation that could potentially affect signalling by other transcription factors. PHB loss may provide a mechanism for progression to CRPC by sensitising PC cells to 'castrate' conditions---that is, low levels of testicular androgens in the continued presence of weak adrenal and dietary androgens.
INTRODUCTION
Prostate cancer (PC) is the most commonly diagnosed cancer in males, 1 and tumour growth is initially androgen-dependent. Cellular and physiological responses to androgens are mediated by the androgen receptor (AR), which is key to PC progression and treatment. 2, 3 There are three sources of androgenic steroids: the testes, which synthesise testosterone from adrenal precursors; the adrenal glands, which secrete the weakly androgenic precursors androstenedione and dehydroepiandrosterone (DHEA); and diet. 5a-reductase enzymes in androgen-dependent tissues such as the prostate convert testosterone into the more potent dihydrotestosterone (DHT), which binds AR with higher affinity. Ligandactivated AR binds to androgen response elements (AREs) located in the regulatory regions of target genes, thus influencing the rate of gene transactivation by recruiting gene activation complexes to the promoters of these genes and dismissing repressive proteins, leading to androgen-dependent cell growth and function. 4 --9 Currently the mainstays of PC treatment are chemical castration using luteinizing hormone releasing hormone (LHRH) analogues to ablate testicular androgens, and anti-androgens, which block androgen signalling at the level of the AR. Initially successful, such hormonal therapies inevitably fail and patients relapse with 'castrate-resistant' PC (CRPC). Resistance results from clonal selection of cells that circumvent androgen requirement by mechanisms including AR gene mutation or receptor amplification. 4 --7,10 --12 Additionally, reduced levels of repressor proteins may increase the activity of the AR due to a lack of repressive action.
One such co-repressor is prohibitin (PHB), 13 previously found to be downregulated by androgen treatment.
14 PHB has multiple roles in the cell, including as a chaperone complex in the inner mitochondrial membrane, 15 an attenuator of Raf-Mek and Akt signalling pathways, 16 and repressor of various transcription factors (including E2F and steroid receptors), and has tumour suppressor, anti-proliferative and cell-cycle regulation activities. 17, 18 PHB has been shown to repress E2F via recruitment of the repressive proteins HDAC1, N-CoR and the chromatincondensing proteins BRG1/Brm. 19, 20 PHB can also repress steroid-activated nuclear receptors, for example the AR 14 and oestrogen receptor, 21 and conversely is capable of activating p53. 22 PHB is a potent transcriptional corepressor of oestrogen receptor a and associates with oestrogen-regulated promoters in the absence of hormone, dissociating after hormone treatment. Interestingly, PHB knockdown reduces the anti-proliferative actions of oestrogen antagonists 23 and PHB recruits BRG1-containing chromatin-remodelling complex to antagonist-bound AR. 24 Additionally, PHB associates with HP1 proteins, 25 involved in the compartmentalisation of chromatin into heterochromatin and euchromatin, 26 and may have a role in facilitating the DNA structural changes required for gene activation and silencing.
Previously, we have shown that PHB can repress AR activity and androgen-stimulated growth of LNCaP PC cells and conversely that RNAi-mediated knockdown of PHB increased AR activity and LNCaP cell growth in response to testicular androgens such as testosterone, both in vitro and in vivo. 27 Therefore, we aimed to determine the mechanism of AR repression by PHB, and what effects the loss of such a repressor would have on AR activity and tumour growth under conditions mimicking those in patients undergoing androgen ablation therapy. Circulating at relatively high levels and unaffected by chemical castration, adrenal androgens are a significant source of androgens in these patients. Therefore, we aimed to study whether the reduction of a repressor such as PHB could indeed cause or contribute towards the apparent 'androgen independence' observed in CRPC and the failure of hormonal therapies.
RESULTS
PHB influences the rate and extent of AR binding to chromatin A pair of doxycycline-inducible LNCaP PC cell lines was established, one ectopically expressing PHB cDNA (LNCaP/Luc/ PHB-cDNA) and one expressing PHB-siRNA (LNCaP/Luc/PHBRNAi), 27 each with its respective empty vector or scrambled control line. Upon removal of soluble nuclear proteins, PHB was evident in nuclear foci (Figure 1a ), number and intensity of which altered with PHB modulation. Fractionation demonstrated that PHB is present in both the cytoplasmic fraction and also the nucleus---both the soluble nuclear fraction, but to a greater extent the chromatin-associated fraction (Figure 1b) . Micrococcal nuclease digestion of chromatin released some of the associated PHB into the soluble nuclear fraction, supporting the PHB-chromatin association. This nuclear pattern is reminiscent of known PHBinteracting proteins HP1 and HDAC1, which colocalise closely with PHB ( Figure 1c ). Chromatin association of PHB was reduced in cells grown in full serum compared with hormonally starved cells (Figure 1d) , with a concomitant increase in soluble nuclear PHB, whereas total and cytoplasmic PHB levels were unchanged. Increased chromatin association of PHB was also seen in serumstarved HeLa cells (Figure 1e ), which neither express AR nor are steroid responsive. Returning these cells to full serum reduced the levels of PHB co-purifying with chromatin within 24 h.
Treating hormone-starved LNCaP cells with androgen revealed increased AR --chromatin association over time with a concomitant reduction in PHB co-purification (Figure 2a , left-hand side). Doxycycline-induced PHB-RNAi reduced the amount of PHB copurifying with the chromatin as expected, but accelerated AR binding, resulting in increased binding at shorter time-points of androgen treatment (Figure 2a right-hand side). Conversely, ectopic expression of PHB cDNA resulted in increased PHB --chromatin association, with a dose-dependent reduction in AR copurification, even in full serum (Figure 2b ). Total levels of AR remained unchanged in each case.
To quantify the effects of PHB loss on the chromatin-binding rate of AR, hormone-starved LNCaP cells were treated with either the potent DHT or the weak androstenedione (both at 10 nM). Without doxycycline, DHT treatment resulted in maximal AR chromatin co-purification at 120 --240 min, whereas doxycyclineinduced PHB-RNAi accelerated this, with maximal AR chromatin co-purification at 30 --60 min. Similarly, with androstenedione treatment: AR --chromatin binding was lower in the absence of doxycycline, whereas PHB-RNAi resulted in a statistically significant increase in AR binding at 120 --240 min (Figure 2c ). No change in rate of AR binding to chromatin was evident in the scrambled RNAi control line.
PHB is displaced from the PSA promoter with androgen treatment Chromatin purification experiments (Figures 1 and 2) showed global chromatin-binding patterns of PHB and AR to be in dynamic opposition. Liganded AR binds to AREs in the promoter and enhancer regions of the well-characterised androgen target gene PSA, and PHB can bind strongly to the PSA promoter in the presence of anti-androgens, 24 but little data is available on the effects of co-repressors on AR binding. To address this, chromatin immunoprecipitation (ChIP) assays were performed.
In hormone-starved LNCaP cells, DHT treatment (2 h) resulted in AR binding to the promoter and enhancer regions as expected, with minimal binding to non-ARE-containing regions (Figure 3a) . In the absence of hormone, PHB binds across the 8 kb PSA promoter region with no apparent regional specificity. DHT treatment led to reduced PHB across all PSA-promoter regions (Figure 3a) , hence this was not limited to ARE-containing regions. Also PHB was recruited to both ARE-containing and ARE-negative regions under hormonally starved conditions as compared with full serum, and was displaced from all three regions by androgen treatment (Figure 3b ), coincident with increased AR binding in the case of the enhancer and promoter regions.
PHB knockdown increases AR binding and binding rate to the PSA promoter As PHB knockdown increased global AR chromatin binding, the effects upon AR binding to AREs in the PSA promoter were studied. DHT increased AR binding to the enhancer and promoter regions as expected, however PHB-RNAi increased AR binding still further (Figure 3c ). DHT treatment reduced PHB binding across all regions, confirming previous results, and PHB-RNAi knockdown reduced this further (Figure 3d ). No change was seen in total AR levels in these cells within this timeframe (see Figure 2a ) and no change in AR or PHB recruitment was seen in the scrambled siRNA control cell line (Supplementary Figure 1a) . Similar data was obtained for the similarly organised androgen-responsive gene KLK2 (Supplementary Figure 1b) .
We then analysed AR binding to the PSA promoter and enhancer in more detail. LNCaP/Luc/PHB-RNAi cells were grown without steroids ( ± doxycycline) for 72 h and then treated with either DHT or androstenedione. DHT treatment promoted AR binding to both regions within 30 min, with binding reduced at 1 h then increasing again at 2 h. PHB-RNAi changed the pattern of AR binding to a more linear increase in binding with no reduction at the 1 --hour timepoint ( Figure 4a ). As the kinetics of androstenedione activity were less rapid, we extended the study to 4 h. Similar results were seen: AR recruitment at 1 h, dropping at 2 h then peaking again at 4 h (Figure 4b ). Doxycycline-induced PHB knockdown caused increased binding of AR to the promoter and enhancer regions with a peak at 1 h and no cyclical pattern evident within this timeframe. Confirming previous results, hormone treatment resulted in a rapid reduction (within 15 min) of PHB binding at the enhancer and at the promoter, with a slight increase at 30 min at the enhancer then a continued reduced level. Unsurprisingly, PHB-RNAi resulted in very low levels of PHB at the enhancer or promoter throughout (Figure 4c ). IgG controls showed no changes with either treatment and a similar pattern was observed for recruitment to the KLK2 enhancer/promoter (Supplementary Figure 2) . PHB knockdown increases AR activity as measured by endogenous and integrated reporter gene expression, but does not affect ligand binding Both testicular and adrenal androgens activate androgen-regulated gene expression, but the less efficient adrenal androgens are required at higher concentrations for similar effects. The ability of these to activate the AR in our cell lines was assayed using the expression of both endogenous androgen-regulated genes (for example, PSA) and an integrated androgen-responsive luciferase reporter. 27 Kinetics of PSA transcript production were studied after treatment with DHT or androstenedione (10 nM) ± doxycycline. DHT-induced PSA transcript levels were increased at 6 h post treatment and further thereafter (Figure 5a , left panel), whereas PHB knockdown resulted in transcript levels peaking earlier (by 2 --4 h) and remaining high thereafter. KLK2 and TMPRS2 showed similar trends (Supplementary Figure 3a) . PHB knockdown also increased the rate of androstenedione-induced PSA transcript production, which was significantly higher from 4 h hormone treatment (Figure 5a, right panel) .
Similarly, we investigated whether the increased AR-binding rate caused by PHB-RNAi could increase the efficacy of various androgens. After 16 h treatment with 100 nM hormone, PSA expression increased 6-fold with DHT (Figures 5b and c left panels), around 3-fold for androstenedione (Figures 5b and c, right panels), whereas DHEA had no significant effect (data not shown). Overexpression of PHB-cDNA caused strong inhibition of androgen-induced PSA expression, whether by DHT or androstenedione ( Figure 5b ). Conversely, doxycycline-induced PHB-RNAi knockdown increased PSA expression in response to both testicular and adrenal androgens (Figure 5c ), significant at doses above 1 nM.
Using the integrated AR luciferase reporter, we found that increasing PHB reduced luciferase activity as previously reported. 27 However, PHB-RNAi resulted in increased luciferase PHB knockdown results in higher baseline levels of acetylated histone H3 in hormonally starved cells PHB is known to recruit histone deacetylases (HDACs) and chromatin-remodelling complexes including HP-1. 19, 20, 25 We saw that PHB reduction resulted in a decrease in HP-1 and HDAC1 association with chromatin ( Figure 6a ), and analysed the chromatin for changes in histone acetylation in response to PHB knockdown. This resulted in an increase in overall acetylation of Histone H3, with increased levels of histone H3-Ac(K9) and Ac(K9) P(S10), even before androgen treatment (Figure 6a ). Additionally, androgen induction of these histone H3 modifications was also higher in the doxycycline-treated samples. Histone H3-Ac(K18) showed no significant changes (data not shown). Conversely, increasing PHB levels by exogenous PHB-cDNA expression resulted in a dose-dependent reduction in global histone H3 acetylation (Figure 6b ).
ChIP analysis of the PSA regulatory region showed androgeninduced enrichment of H3-Ac(K9) across most of the promoter region as expected; however, when PHB was reduced, a further enrichment was observed most notably at the enhancer and negative regions both before and after DHT treatment (Figure 6c) . Interestingly, the RNAi-mediated reduction in PHB also increased levels of acetylated histone H3 at the promoters of the inducible TAP1 and Cyclin D1 genes, but had little effect at the constitutively active ß-actin gene (Figure 6d ).
PHB knockdown increases LNCaP cell growth in response to testicular and adrenal androgens both in vitro and in vivo Having previously shown that PHB-RNAi increased prostate cell and tumour growth in response to testosterone, 27 we tested whether it could similarly increase the response to adrenal androgens and translate into a tumour-growth effect. Interestingly, in the absence of doxycycline we observed no cell growth in response to DHEA at doses up to and including 10 nM for 96 h (Figure 7a and data not shown). In culture, PHB-RNAi increased cell growth in response to all androgens: DHT, androstenedione and DHEA (10 nM) (Figure 7a ). PHB-RNAi also increased the percentage of cells in S-phase, under all conditions tested (Figure 7b ).
Established PC therapies do not affect adrenal androgen production. This is confirmed by the fact that serum androstenedione in healthy human males has a normal range of 1.7 --10 nM, whereas samples collected from patients treated with LHRH analogues (Leuprorelin or Goserelin) alone (androgen ablation) or plus bicalutamide (maximal androgen blockade) showed androstenedione values within this normal range ( Table 1) . As PHB-RNAi increased AR activity in response to these weaker ligands, we examined in xenograft models whether normal serum levels of these androgens would be sufficient to maintain PC tumour growth in vivo when PHB is reduced. Adrenal androgen production in rodents is maximal postnatally, but drops to undetectable levels post-puberty 28 as adult males lack 17a-hydroxylase in the adrenal cortex. 29 Androgen synthesis is mainly testicular, from multiple precursors, for example, corticosterone, pregnenolone or acetate, produced in the liver or peripheral tissues. 30 --32 Orchidectomised male mice showed undetectable levels of both testosterone and androstenedione (Table 1) , thus specific androgens could be supplemented to study individually. Androstenedione supplementation increased serum androstenedione to 0.3 --2.1 nM, coincident with the normal range (0.3 --2.0 nM), and no significant effect was seen on serum testosterone, although minimal peripheral tissue conversion cannot be ruled out. Androstenedione supplementation, therefore, mimics serum conditions of men undergoing therapy whose circulating testosterone levels are significantly reduced, but who have normal androstenedione levels. LNCaP/Luc/PHB-RNAi xenografts were thus grown under these conditions. Mice were given daily testosterone supplementation (resulting in serum levels of 7--10 nM) until tumour burden was confirmed, and the tumours given a relative tumour volume (RTV) of 1. Mice were then separated into treatment groups: continued testosterone treatment, switched to androstenedione, or vehicle only (all ± doxycycline). In testosterone-treated castrated mice, LNCaP tumours grow with a mean doubling time of 20 days, whereas in vehicle-treated mice tumours stop growing and shrink within 48 h. 27 Tumours in androstenedione-treated castrated mice did not show rapid tumour growth as seen for testosterone, but unlike vehicle controls, tumours were maintained with no regression (Figure 7c , dashed line). Under the same conditions plus PHB-RNAi, tumours showed a statistically significant increase in RTV as compared with control (Figure 7c) , that is, PHB reduction promoted androstenedione-induced tumour growth in vivo. Figure 7d summarises RTVs for vehicle, androstenedione and testosterone ( ± doxycycline) at the end of the experiment.
DISCUSSION
We set out to analyse the mechanisms by which PHB reduction increases AR activity, and its possible contribution to the 'androgen-independent' phenotype of CRPC. Although PHB has no specific DNA-binding motifs, a large fraction is chromatinassociated, which alters according to treatment (increased in serum-starved cells compared with either androgen-treated LNCaP cells or serum-stimulated HeLa cells). PHB also associated closely with HP-1 and HDAC1 proteins, which are known to be strongly chromatin-associated. PHB dissociation from chromatin may be a requirement for (or a result of) cell cycle initiation regardless of initiation factor, be it androgens in LNCaP cells or other serum-derived growth factors in HeLa cells. PHB knockdown increased the amount and rate of AR-chromatin association in response to DHT and androstenedione, whereas overexpression was inhibitory, suggesting AR and PHB have dynamic and opposite roles/activities. PHB was also present upon the promoters of non-AR-regulated genes including the constitutively active ß-actin and the interferon-inducible gene TAP1, 33 as well as Cyclin D1, which is indirectly regulated by androgens (See also Supplementary Figure 6a) . PHB knockdown influenced the levels of acetylated histone H3 at these promoters also, indicating a more global phenomenon than simply affecting directly androgen-regulated genes. The widespread increase in histone acetylation did not, however, cause a global increase in gene expression (Supplementary Figure 6b) . Basal Cyclin D1 expression increased, perhaps in part explaining the increased cell cycle entry seen upon PHB knockdown. Basal TAP1 expression was reduced upon PHB knockdown but upon IFN treatment, induction was moderately increased (Supplementary Figure 7c) . Caspase 7 and YY1 expression were oppositely regulated, being reduced and increased respectively upon PHB knockdown, as previously reported by Joshi et al. 34 This supports the growing body of evidence that PHB can have diverse effects on many gene promoters, and also that its effects appears to be mainly repressive in the case of androgen-regulated genes.
ChIP at the PSA and KLK2 genes showed DHT-induced binding of AR to ARE-containing regions at 2 h, whereas PHB binding decreased across all regions. Reducing PHB protein levels resulted in enhanced AR binding, supporting the theory that PHB and AR binding are in opposition, if not mutually exclusive. The temporal association of AR revealed a complex pattern of association and disassociation such as reported previously. 35, 36 PHB was present on all regions in hormonally starved cells but rapidly dissociated in DHT-treated cells. PHB-RNAi changed the pattern of AR binding: AR remained bound, with no fluctuation within the time studied. Work from the Gannon laboratory on oestrogen receptor promoter-binding describes an initial unproductive cycle and then subsequent transcriptionally productive cycles. 37 A timecourse of DHT-treated LNCaP cells showed that PSA transcripts could be detected much earlier when PHB levels were reduced. Additionally, PHB-RNAi increased histone H3 acetylation (Ac-K9) and increased DNase sensitivity of the chromatin (Supplementary Figure 7) both indicators of chromatin flux (or possible artefacts of the cell cycle-promoting effects of PHB loss). PHB loss may alter histone modifications (such as H3 acetylation, as shown here) such that chromatin is in a more active state, which in the case of androgen responsive genes may eliminate the unproductive cycle of steroid receptor binding. Alternatively, however, PHB may be required for hormone starvation-induced chromatin silencing, with its loss preventing the full effects of such starvation on silencing of target genes. Regardless, PHB reduction increases AR efficiency.
Although associated with chromatin and found at AR-regulated regions, PHB protein could not be co-purified with oligonucleotides containing a consensus ARE or larger DNA sequences representing PSA regulatory regions (data not shown). Further, no DNA-binding sequence has been described for PHB, and it associates with the nuclear matrix, 38 suggesting it may bind chromatin with higher-order structure, strongly supported by its recruitment of Brm/Brg chromatin modifiers and association with heterochromatin-binding protein 1 (HP1), 25 as well as its association with many and varied gene promoters. In the context of androgen signalling, PHB may modulate AR binding to AREs via altering chromatin conformation, and/or by recruiting repressive chromatin-remodelling complexes to the region in the absence of ligand. Repressive complex recruitment by PHB is essential for anti-androgen effects. 24 As adrenal androgens possess weak antiandrogen activity, 39 the loss of a repressor protein such as PHB not only increases the effects of weak androgens but also inhibits their weak anti-androgenic effects, thereby potentially greatly increasing their potency. Modulating PHB within LNCaP PC cells influenced AR activity with PHB-RNAi promoting increased androgen-stimulated cell cycle entry, increased endogenous and reporter gene transcription, and increased tumour xenograft growth in vivo. 27 We examined whether this increased AR activity would cause weak AR agonists to become significant activators. Although PHB ectopic expression inhibited all hormone-induced activity (data not shown), PHB-RNAi amplified the response to all androgens, reducing the effective concentration required to give maximum effect approximately 10-fold. It has previously been reported that in the C4-2b PC cell line, which is derived from LNCaP but more aggressive in vivo, PSA is expressed even in the absence of added DHT, when very small amounts of AR are present at the PSA promoter. 40 Upon investigation, we found that these cells exhibit approximately 20% lower levels of endogenous PHB than LNCaP cells---as do several other more aggressive PC cells (Supplementary Figure 8) . Reducing PHB levels still further in one such line (VCaP) resulted in an increased PSA response. It is tempting to speculate that the effective increased PSA response in C4-2 cells as compared with LNCaP may reflect, at least in part, the decreased PHB levels and possible that this may also contribute to their more aggressive phenotype.
LNCaP tumour xenografts growing in castrated mice treated with androstenedione mimicked conditions in androgen-ablated PC patients. Androstenedione increased tumour volume as compared with vehicle control, but this was not statistically significant until PHB was reduced by RNAi. As we had shown that PHB reduction alters the temporal dynamics of AR activity, facilitating binding of liganded AR to DNA and consequently ELISA measurement of serum androstenedione levels from human males---both normal and patients undergoing treatment regimens for prostate cancer (upper panel). ELISA measurement of serum androstenedione levels from male nude mice---either intact or surgically castrated with and without androgen supplementation (lower panel). increasing androgenic activity of weak adrenal androgens, it is likely that this significant tumour growth caused by androstenedione is a consequence of reduced PHB levels. In support of this, reintroducing PHB into the depleted cells reversed the stimulatory effects of PHB knockdown, in the presence of DHT or androstenedione. Adrenal or dietary-derived androgens may therefore become more significant in PC patients, as they are unaffected by androgen ablation regimens and may become sufficient to promote or maintain tumours under conditions of 'androgen ablation'. Further, this supports our hypothesis (Dart et al., 2009 ) that increasing PHB levels may be of therapeutic benefit in CRPC patients. It is important to note that, although we have also shown that reducing PHB can also increase the stimulatory effects of low levels of potent androgens such as DHT in terms of increasing target gene activity, we have not proven whether this involves dose-dependent alterations in rate of AR chromatin binding or translates into a growth effect. It thus remains an untested possibility that reduced PHB could also exacerbate the effect of any residual low levels of testicular androgens, which may be present in CRPC patients.
The AR-mediated downregulation of PHB 14 may be exacerbated during PC development, especially in tumours with AR ligandbinding domain mutations, leading to increased sensitivity to adrenal androgens. This study thus supports the requirement for androgen ablation that additionally targets adrenal androgen synthesis, such as CYP17 inhibitors. PHB loss is a potential mechanism that may at least partially contribute to the increasingly significant burden of castrate-resistant PC, whereas corepressors and co-activators of AR provide new avenues for research into the treatment of recurrent PC.
MATERIALS AND METHODS

Cell Culture
LNCaP and VcaP cells were maintained at 37 1C, 5% CO 2 in RPMI medium with 10% foetal bovine serum (First Link UK, Ltd, Brierley Hill, UK). All LNCaP/Luc/PHB cells were maintained at 37 1C, 5% CO 2 in RPMI medium with 10% dox-free foetal bovine serum (Clontech, Palo Alto, CA, USA), 12 mg/ml blasticidin (Sigma, Poole, UK), 0.3 mg/ml zeocin (Invitrogen, Paisley, UK), and 500 mg/ml G418 (Sigma). HeLa cells were maintained in DMEM medium (Sigma) with 10% fetal bovine serum (First Link UK). All media was supplemented with 2 mM L-glutamine, 100units/ml penicillin, 100 mg/ml streptomycin (Sigma). 72 h before androgen exposure, medium was replaced with 'starvation medium' consisting of phenol red-free RPMI (or DMEM) medium, supplemented with 5% charcoal-stripped foetal bovine serum (First Link UK).
Luciferase assay
Cells were lysed in reporter lysis buffer (Promega). Lysate was mixed with luciferin substrate and light emission measured using the Steadylite luciferase assay kit (Perkin-Elmer, Warrington, Cheshire, UK) in a Topcount luminometer (Packard Instrument Co, Meriden, CT, USA).
RNA extraction and RT--PCR
Total RNA samples were prepared using commercial kits (Qiashredder and RNeasy, Qiagen) and converted to cDNA using the SuperScript First-Strand Synthesis system (Invitrogen).
Taqman quantitative PCR
Reactions were performed in triplicate on cDNA samples in 96-well optical plates on an ABI Prism 7900HT system (Applied Biosystems, Warrington, UK). Reactions consisted of 2 ml cDNA, 7 ml PCR-grade water, 10 ml 2 Â TaqMan Universal PCR Master Mix (Applied Biosystems), 1 ml Taqmanspecific assay probes (Applied Biosystems) for PSA, TMPRSS2, KLK2 and L19. Parameters were: 50 1C for 2 min, 95 1C for 10 min, 40 cycles of 95 1C for 15 s and 60 1C for 1 min. Data was recorded using Sequence Detector Software (SDS version 2.3; PE Applied Biosystems, Carlsbad, CA, USA). Levels were normalised to GAPDH or L19.
Chromatin Isolation and In Situ Cell Fractionation
Cells (4 Â 10 7 cells/ml) were suspended in buffer A (10 mM hydroxyethyl piperazineethanesulfonic acid pH7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 1 mM DTT, protease inhibitor cocktail (Sigma)). Triton X-100 was added (0.1%), and incubated on ice for 5 min. Nuclei were collected by centrifugation for 4 min at 1200 g with supernatant collected as the cytoplasmic fraction. Nuclei were lysed in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease inhibitor cocktail) and chromatin was collected by centrifugation for 4 min at 1800 g, with supernatant collected as a soluble nuclear fraction. The chromatin pellet was washed twice in buffer B and re-suspended in Laemmli buffer.
For in situ fractionation for immunofluoresent staining, cells were grown on coverslips, washed in phosphate-buffered saline (PBS) and fractionated by adding buffer A with 0.5% triton X-100, on ice for 5 min. Cells were washed twice in PBS and fixed with 1% formaldehyde for 10 min.
Histone extraction
Cells were lysed for 10 min (4 1C) in lysis buffer (PBS, 0.5%. TritonX-100, 2 mM phenylmethanesulfonylfluoride, 5 mM NaButyrate, protease inhibitor cocktail) at 10 7 cells/ml. Nuclei were pelleted by centrifugation at 2000 g for 10 min and washed in lysis buffer. Nuclei were extracted in 0.2N HCl overnight at 4 o C Proteins were precipitated by TCA (100%) and pelleted at 16 000 g for 10 min, acetone-washed and air-dried, before dissolving in lysis buffer.
Immunoblotting
Immunoblotting was carried out as described. 27 Primary antibodies were; b-actin (Abcam, Cambridge, MA, USA @1:5000), PHB (Thermo Fisher Scientific, Cheshire, UK @1:1000), AR (Dako UK Ltd, Ely, UK), Histone H3 (Sigma;1:2000), Histone H3-Ac(K9), H3 Ac(K9) P(S10), H3 Ac(K18), (New England Biolabs (UK) Ltd, Hitchin, UK, @1/500), HP1 (Active motif, USA; 1: 500), HDAC1 (Sigma; 1:1000). Peroxidase-labelled secondary antibodies (Dako) were used at 1:2000. The PVDF membrane (Millipore, Consett, UK) was then incubated in chemiluminescent substrate (GE Healthcare Life Sciences, Little Chalfont, UK) and light emission detected by autoradiography.
Chromatin Immunoprecipitation
Cells (1 Â 10 7 ) were grown in starvation medium for 3 days, then treated with hormone (10 nM MB) for 0 --2 h. ChIP was performed on formaldehyde cross-linked cell samples essentially as described. 41 
Confocal microscopy
Cells grown on glass coverslips were fixed in 1% formaldehyde for 10 min. For in situ fractionation, cells were permeabilised in buffer (10 mM Pipes pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, 0.5% Triton-X100) and washed several times in PBS before fixation. Coverslips were blocked with 10% rabbit serum (Dako UK Ltd, Ely, UK) for 30 min. Mouse anti-human PHB antibody (Neomarkers) was applied for 1 h followed by PBS washes. Fluorescein isothiocyanate (FITC)-labeled secondary antibody (Alexa @ 1:50) was then applied for 1 h and then washed in PBS, mounted on slides with Vectorshield/DAPI (Vector Laboratories Ltd, Peterborough, UK) and visualised on Zeiss Meta 512 confocal microscope (Carl Zeiss Ltd, Welwyn Garden City, UK).
Sulphorhodamine B assay for cell growth Cell growth was measured by sulphorhodamine B assay as previously described. 14 
